NEWS

FacebookTwitter Google+LinkedIn

03.08 2016

Ginolis Ltd. transfers electrode production line to SciBase

Ginolis’s successful partnership with SciBase reaches final milestone. Ginolis has developed and manufactured a semi-automated electrode production line which has now been approved by Scibase thus concluding the agreement to transfer electrode production to Scibase. The desktop automation line, which is based on the modular Delilah robotic platform, assembles Nevisense electrodes for use in the unique point-of-care device for the accurate detection of malignant melanoma.

“We would like to take the opportunity to thank Ginolis for their professional services and the high quality of the electrodes produced” says Simon Grant, CEO at SciBase.

As part of the transfer agreement, two former Ginolis employees, who have been involved in the production of the electrodes, are now employed by SciBase. The production itself will continue from Ginolis’ current premises in Uppsala.

 

Further information:

Mike Read, EVP
Ginolis Ltd. | +46 70 528 9245 | .(JavaScript must be enabled to view this email address)

Simon Grant, CEO
Scibase | +46 72 887 43 99| .(JavaScript must be enabled to view this email address)

 

About Ginolis

Ginolis Ltd. is a global provider of high precision liquid handling and intelligent desktop automation for the global medtech and diagnostics industries. The company’s desktop robotic platforms are characterized by high precision and modularity.

Ginolis is privileged to work in co-operation with many of the world’s leading diagnostic companies. Established in 2010, Ginolis is privately owned and headquartered in Oulu, Finland, with offices in Uppsala, Sweden and San Diego, USA. For more information visit www.ginolis.com.

 

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer.

Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on  http://www.scibase.com.